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A B S T R A C T
Objectives: MCL1 is an anti-apoptotic BCL2 family member that is highly expressed in various malignant tumors.
However, little is known about the role of MCL1 in KRAS-mutant lung adenocarcinomas. In this study, we aimed
to clarify whether MCL1 could be a therapeutic target in KRAS-mutant lung adenocarcinomas for which no
effective molecular targeted drugs are available.
Materials and methods: We examined to what extent MCL1 knockdown either alone or in combination with MEK
inhibitor trametinib suppressed growth or induced apoptosis in the KRAS-mutant lung adenocarcinoma cell line
H441 and EGFR-mutant lung adenocarcinoma cell line H1975. Furthermore, we investigated the therapeutic
effects of dual inhibition of MCL1 and Bcl-xL, another anti-apoptotic BCL2 family member, in these two cell
lines.
Results: MCL1 knockdown alone did not induce apoptosis in H441 or H1975 cells. However, MCL1-depleted
H441 and H1975 cells underwent apoptosis and decreased in number in the presence of trametinib. We also
confirmed that combined therapy by MCL1 knockdown and trametinib almost completely suppressed the growth
of H441 cells in vivo. Moreover, dual knockdown of MCL1 and Bcl-xL induced extensive apoptosis in H441 and
H1975 cells.
Conclusion: These findings suggest that combined treatments of MCL1 knockdown and trametinib or dual in-
hibition of MCL1 and Bcl-xL would be effective therapies for lung adenocarcinomas including the KRAS-mutant
subtype.
1. Introduction
Lung cancer is the leading cause of cancer deaths worldwide with a
5-year survival rate of 16% among patients with all stages of the disease
[1]. The majority of lung cancers are classified as non-small cell lung
cancer (NSCLC), and adenocarcinoma is the most common histological
subtype of NSCLC. Certain subtypes of lung adenocarcinomas are
treatable by effective molecular targeted drugs. For example, tyrosine
kinase inhibitors against epidermal growth factor receptor (EGFR) and
anaplastic lymphoma kinase (ALK) are highly effective against EGFR-
mutant and ALK fusion-positive lung adenocarcinomas, respectively
[2]. However, there are no effective treatments for KRAS-mutant lung
adenocarcinomas, which account for one third of lung
adenocarcinomas [3]. Constitutively activated mutant KRAS protein is
technically difficult to suppress by small molecule inhibitors [4]. Since
mutant KRAS constantly activates MEK (MAPK/ERK kinase), it has been
regarded as an alternative therapeutic target for KRAS-mutant tumors
[5,6]. However, even the MEK inhibition strategy is rather difficult,
because second line treatment with trametinib, a MEK inhibitor, did not
significantly improve progression-free survival compared with doc-
etaxel alone in a clinical trial for KRAS-mutant lung cancer [7]. How-
ever, we have recently reported that trametinib suppresses the ex-
pression of survivin and induces senescence in KRAS-mutant lung
adenocarcinoma cells in vitro [8]. These findings raise the possibility
that treatment with trametinib might have a certain efficacy against
KRAS-mutant lung adenocarcinomas.
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Apoptosis can be induced via two main pathways, the cell extrinsic
pathway and cell intrinsic pathway [9]. The cell intrinsic pathway is
regulated by the BCL2 family of proteins, which shares a common BH
(BCL2 homology) 3 domain. The “BH3-only” family of proteins, in-
cluding BID, BAD, BIM, BMF, PUMA, and NOXA, possesses only the
BH3 domain and promotes apoptosis induction, while the anti-apop-
totic proteins, such as BCL2, Bcl-xL, BCL-W, A1/Bfl1, and MCL1, have
additional BH1 and BH2 domains. Upon activation of BH3-only pro-
teins, another proapoptotic family of proteins, the “BAX” family (BAK,
BAK, and BOK), forms pores in mitochondria, resulting in cytochrome C
release and apoptosis induction of the cell. Of note, BIM plays a parti-
cularly important role in apoptosis induction of lung adenocarcinoma
cells [10,11]. The anti-apoptotic proteins bind to BH3-only proteins or
BAX family members and prevent induction of apoptosis [9]. The bal-
ance between proapoptotic and anti-apoptotic members of the BCL2
family of proteins determines whether apoptosis occurs [12].
Several BH3-only protein mimetics (hereafter called BH3 mimetics)
have been developed to promote apoptosis of cancer cells, and one of
the representatives is ABT-263 (also known as navitoclax). The effi-
cacies of ABT-263 alone or combined with other molecular targeted
drugs against NSCLC have been investigated in preclinical studies
[13,14]. Interestingly, ABT-263 inhibits the anti-apoptotic functions of
BCL2 and Bcl-xL, but is ineffective against those of MCL1. Although
there were no BH3 mimetics against MCL1 until recently, S63845 has
been developed and considered promising [15]. However, its efficacy
against lung cancer has not been elucidated.
Although the importance of Bcl-xL in the survival of KRAS-mutant
lung adenocarcinoma cells has already been recognized [16], the extent
to which MCL1 contributes to their survival has not been fully clarified.
In this study, we demonstrate that MCL1 may be a new therapeutic
target in well-differentiated KRAS-mutant lung adenocarcinomas.
2. Materials and methods
2.1. Kaplan-Meier plotter database
We used the Kaplan-Meier Plotter online service (http://kmplot.
com/analysis/index.php?p=background) to clarify whether highMCL1
mRNA expression was associated with an unfavorable outcome of pa-
tients with lung adenocarcinomas [17].
2.2. Cell culture and drug treatments
Two KRAS-mutant lung adenocarcinoma cell lines, NCI-H441
(G12 V) and NCI-H460 (Q61 H), and the EGFR-mutant lung adeno-
carcinoma cell line NCI-H1975 (L858R+T790M) were obtained from
the American Type Culture Collection (Manassas, VA, USA) and main-
tained at 37 °C in a humidified incubator with 5% CO2. The cells were
cultured in RPMI-1640 (Nacalai Tesque, Kyoto, Japan) with 10% fetal
bovine serum and antibiotics. Two MEK inhibitors, trametinib (AdooQ
BioScience, Irvine, CA, USA) and selumetinib (AdooQ BioScience), and
three BH3 mimetics, ABT-263 (AdooQ BioScience), S63845 (Cayman
Chemical, Ann Arbor, MI, USA), and WEHI-539 (AdooQ BioScience)
were also used in this study.
2.3. Immunofluorescence staining
Immunofluorescence staining was conducted as previously de-
scribed for the expression of MCL1 in H441 and H1975 cells [18,19].
Briefly, cells grown on 35-mm glass bottom, collagen-coated dishes
(D11134 H; Matsunami Glass, Osaka, Japan) were fixed with acetone/
methanol (1:1) at −20 °C for 10min. After the cells were rinsed with
Tris-buffered saline (TBS), they were blocked with 3% BSA/TBS for
60min at room temperature. The samples were then incubated over-
night at 4 °C with the primary antibody against MCL1 (sc-819; 1:200:
Santa Cruz Biotechnology, Dallas, TX, USA). The samples were
subsequently incubated with a secondary antibody, Alexa Fluor 488-
conjugated goat anti-rabbit IgG (A-11008; 1:400; Thermo Fisher Sci-
entific Japan, Yokohama, Japan). The cells were finally observed under
an inverted microscope (IX-71; Olympus, Tokyo, Japan) and photo-
graphed by a camera (DP80; Olympus).
2.4. RNA interference assay
Cells (3× 106) were plated in 94-mm culture dishes and transfected
with negative control (NC) siRNA duplexes (1027281; Qiagen,
Valencia, CA, USA) or siRNA duplexes targeting MCL1 and Bcl-xL using
Lipofectamine RNAiMAX reagent and OPTI-MEM I (Thermo Fisher
Scientific), as described previously [18–20]. Two types of siRNA du-
plexes were used for transient MCL1 (encoded by the MCL1 gene) or
Bcl-xL (encoded by the BCL2L1 gene) knockdown: Silencer Select Va-
lidated siRNA (Ambion #s8583, termed MCL1 siRNA #1 in this study;
Thermo Fisher Scientific), Silencer Select Pre-designed siRNA (Ambion
#s8585, termed MCL1 siRNA #2; Thermo Fisher Scientific), and Si-
lencer Select Validated siRNAs (Ambion #s1920 and #s1921, termed
Bcl-xL siRNA #1 and #2, respectively; Thermo Fisher Scientific). The
final concentration of the siRNA used in each in vitro experiment was
10 nM. Downregulation of targeted gene expression was verified by
western blot analysis.
2.5. Assessment of cell viability and apoptosis
The number of viable cells was estimated using a CellTiter Glo 3D
Cell Viability Assay (Promega, Madison, WI, USA), according to the
manufacturer’s instructions. The luminescence of viable cells was
measured by the Infinite 200 microplate reader (Tecan Japan,
Kawasaki, Japan). All results are presented as the means ± SD.
Apoptosis was assessed by western blot analysis of cleaved poly (ADP-
ribose) polymerase 1 (PARP-1) or cleaved caspase 3, as described pre-
viously [19,20].
2.6. Western blot analysis
Western blot analysis of thyroid transcription factor 1 (TTF-1),
PARP-1, Bim, total ERK1/2, phospho-ERK1/2, and β-actin was per-
formed as described previously [18–20]. Additional primary antibodies
used in the present study were anti-MCL1 (sc-819; 1:1,000; Santa Cruz
Biotechnology), anti-Bcl-xL (#2764; 54H6; 1:1,000; Cell Signaling
Technology Japan, Tokyo, Japan), anti-BCL2 (sc-509; 1:500; Santa Cruz
Biotechnology), and anti-cleaved caspase 3 (#9661; Asp175; 1:1,000;
Cell Signaling Technology Japan). The cells were lysed in NuPAGE LDS
Sample Buffer (Thermo Fisher Scientific). The cell lysates (15 μg total
protein in each well) were separated by SDS-PAGE (SuperSep Ace,
5–20%, 13 wells; Wako Pure Chemicals, Osaka, Japan) and then
transferred onto polyvinylidene difluoride membranes. The membranes
were blocked by incubation with 3% non-fat dry milk in TBS for 1 h at
room temperature and then incubated overnight at 4 °C with one of the
abovementioned primary antibodies. The membranes were washed
three times and then incubated for 1 h at room temperature with a
species-specific horseradish peroxidase-conjugated secondary antibody
(NA931 or NA934; GE Healthcare, Buckinghamshire, UK). Blots were
visualized using Supersignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific).
2.7. Crystal violet staining
Cell culture plates were placed on ice, and the cells were washed
twice with cold PBS and then fixed in ice-cold 100% methanol for
10min. Following fixation, the cells were stained with a 0.5% crystal
violet solution (Tokyo Chemical Industry, Tokyo, Japan) diluted in 25%
methanol for 10min at room temperature. Plates containing stained
cells were then photographed using a digital camera (D610; Nikon,
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Fig. 1. Combined therapy by MCL1 knockdown and trametinib suppresses proliferation and induces apoptosis in H441 and H1975 cells. (A) Kaplan-Meier curves for
overall survival according to mRNA expression levels of MCL1 in patients with lung adenocarcinomas (n= 720). Data were obtained from the Kaplan‑Meier Plotter
database [17]. (B) Immunofluorescence of MCL1 in H441 and H1975 cells. Scale bars, 20 μm. (C–E) Effects of the combined therapy by MCL1 or Bcl-xL knockdown
and trametinib on the viability of H441 and H1975 cells. Cells were transfected with NC siRNA, MCL1 siRNA (#1 or #2), or Bcl-xL siRNA (#1 or #2) (10 nM each) as
indicated and then cultured for 48 h. Cells were then untreated or treated with trametinib (10 nM) for another 72 h. Cell viability was assessed in triplicate. Results
are shown as means ± SD. *P < 0.05, **P < 0.01. (F) Crystal violet staining of viable cells. Cells were treated as described in (C–E). (G) Western blot analyses of
the effects of the combined therapy in H441 and H1975 cells. Cells were treated as described in (C–E).




Total RNA extraction, and quantitative or conventional RT-PCR
analyses of mRNA expression were carried out as described previously
[19–21]. The following PCR primers were purchased from Qiagen
(QuantiTect Primer Assay): β-actin, encoded by the ACTB gene
(Hs_ACTB_1_SG); BCL2 (Hs_BCL2_1_SG); MCL1 (Hs_MCL1_1_SG); Bcl-xL,
encoded by the BCL2L1 gene (Hs_BCL2L1_1_SG); TTF-1, encoded by the
NKX2-1 gene (Hs_NKX2-1_1_SG). The amount of β-actin mRNA in each
sample was used to standardize the quantity of target mRNAs. Relative
mRNA expression levels were calculated by the comparative ΔΔCT
method and are presented as the averages of triplicate experiments.
2.9. Mouse tumor xenograft model
All animal experimentation was conducted in accordance with a
protocol approved by the Animal Committee at Sapporo Medical
University. The experiments were performed using 6–8-week-old fe-
male mice (n= 20) (KSN/Slc nude mice; Hokudo, Sapporo, Japan).
This study used a minimum of five mice per group. The mice were
maintained under comfortable conditions (temperature: 20–26 °C; hu-
midity: 40–60%) and had free access to food and water. The weights of
mice upon purchase and sacrifice were 22 g and 24 g on average, re-
spectively. At 6 h after NC siRNA (Ambion In Vivo Negative Control
siRNA #1; Thermo Fisher Scientific) or MCL1 siRNA #1 transfection,
5× 106 H441 cells were collected in 50 μl RPMI-1640 and then mixed
with 50 μl Matrigel (Corning, Corning, NY, USA). The cell/Matrigel
mixture was subcutaneously injected into the right flanks of mice an-
esthetized by inhalation of isoflurane (3–5%; Pfizer, New York, NY,
USA). Each mouse received a single injection of H441 cells, and thus
developed a single tumor nodule. At 12 and 22 days after the injection,
we injected AteloGene (Koken, Tokyo, Japan) containing NC siRNA
(n=10) or MCL1 siRNA (n= 10) near the tumor nodules to administer
the siRNA continuously. Mice were administered the vehicle (n= 10)
or trametinib (0.6 mg/kg) (n=10) orally once daily for 20 days (days
12–32 post-injection of the cells) [22,23]. Trametinib was dissolved in
10% Cremophor EL, 10% PEG400, and 80% dH2O (Nacalai Tesque).
The mice were monitored daily for body weight and general conditions.
Tumors were measured twice weekly using a caliper, and their volume
was calculated by the following formula: 0.5 × (width)2 × length.
After the observation, mice were anesthetized by inhalation of iso-
flurane and then sacrificed by cervical dislocation. The tumor nodules
were subsequently removed for weighing and histology [hematoxylin
and eosin (H&E) staining].
2.10. Statistical analysis
Differences in the viability of untreated and treated cells were
evaluated by Dunnett’s test. One-way analysis of variance (ANOVA)
followed by the Tukey-Kramer multiple comparison test was performed
to evaluate the effects of MCL1 knockdown and MCL1 depletion plus
therapy with trametinib on cells and tumor xenografts. A P-value of less
than 0.05 was considered significant. All statistical calculations were
performed using JMP software (JMP for Windows version 7, SAS
Institute Japan, Tokyo, Japan).
3. Results
3.1. Combined therapy by MCL1 knockdown and trametinib suppresses
proliferation and induces apoptosis in KRAS-mutant lung adenocarcinoma
cells
First, we searched the Kaplan-Meier Plotter for an association be-
tween the MCL1 mRNA expression level and outcome of lung
adenocarcinoma patients, and found that the overall survival of patients
with high MCL1 expression (n=360) was markedly shorter than that
of patients with low MCL1 expression (n= 360) (hazard ratio, 1.76;
P= 2.7e−6) as shown in Fig. 1A [17]. Similar effects of the MCL1
expression on survival were observed even in patients with lung ade-
nocarcinomas of stage I (Supplementary Fig. S1). We then found that
MCL1 protein was diffusely expressed in the cytoplasm of the KRAS-
mutant lung adenocarcinoma cell line H441 and EGFR-mutant lung
adenocarcinoma cell line H1975 (Fig. 1B). MCL1 knockdown by RNAi
alone did not affect proliferation (Fig. 1C, F) or induce apoptosis in
H441 or H1975 cells (Fig. 1G). Trametinib treatment alone slightly
suppressed the growth of cells, but did not induce apoptosis, although
BIM was dephosphorylated and accumulated by the treatment (Fig. 1C,
F, G). Combined therapy by trametinib and MCL1 depletion, however,
significantly suppressed growth and induced apoptosis in H441 and
H1975 cells (Fig. 1C, F, G). These findings suggest that the combined
therapy by MCL1 knockdown and trametinib has a certain efficacy
against lung adenocarcinoma cells regardless of differences in their
driver mutation.
We then compared the therapeutic effects of Bcl-xL knockdown with
those of MCL1 silencing. As mentioned above, MCL1 knockdown alone
had no effect on proliferation or apoptosis of H441 and H1975 cells,
whereas Bcl-xL knockdown alone induced apoptosis, resulting in de-
creased viability of H441 cells (Fig. 1D, F, G). Similar, but less promi-
nent, effects of Bcl-xL silencing on viability and apoptosis of H1975
cells were also observed (Fig. 1D, F, G). As expected, the combined
treatment with Bcl-xL knockdown and trametinib almost completely
suppressed proliferation and induced apoptosis in the two examined
cell lines (Fig. 1D, F, G). Interestingly, combined therapy by trametinib
and Bcl-xL knockdown was more efficacious against H441 cells than
combined therapy by trametinib and MCL1 knockdown, whereas
H1975 cells were more sensitive to the latter (Fig. 1E–G). We were able
to substitute selumetinib, another MEK inhibitor, for trametinib in the
treatment of the two cell lines (Supplementary Fig. S2A–C). In addition,
S63845, the selective inhibitor of MCL1, was able to replace MCL1
knockdown, while ABT-263, the BCL2/Bcl-xL inhibitor, was a substitute
for Bcl-xL knockdown (Supplementary Fig. S3A, B). These findings
collectively suggest that MCL1 and Bcl-xL play certain roles in the
survival of lung adenocarcinoma cells, and that each cell line depends
on MCL1 and Bcl-xL for survival to varying extents.
3.2. Combined therapy by MCL1 knockdown and trametinib effectively
suppresses the growth of H441 cells in vivo
To confirm the efficacy of the combined therapy by MCL1 knock-
down and trametinib in vivo, we implanted NC siRNA- or MCL1 siRNA-
transfected H441 cells into subcutaneous tissues of mice. Since the ef-
ficacy of pretransfected siRNA was transient, we administered siRNA to
the tumor nodules using Atelocollagen at the start of trametinib therapy
(day 0) and 10 days later (day 10). As expected, based on in vitro
analyses, the MCL1 siRNA-transfected cells grew steadily and compar-
ably to NC siRNA-transfected cells, whereas MCL1-depleted nodules
hardly increased in size in the presence of trametinib (Fig. 2A–C). For
NC siRNA-transfected H441 cells, although trametinib suppressed the
growth of these cells to some extent, there were no statistically sig-
nificant differences in the tumor volume (P=0.17) or weight
(P= 0.09) (NC si alone versus NC si+ trametinib) (Fig. 2A–C). In ad-
dition, representative pathological findings seem to support the ther-
apeutic effects of the four groups (Fig. 2D). These results clearly de-
monstrate that MCL1 knockdown enhances the efficacy of trametinib in
KRAS-mutant H441 cells in vivo.
3.3. Well-differentiated lung adenocarcinoma cells undergo extensive
apoptosis after silencing both MCL1 and Bcl-xL
Next, we focused on the role of the three major anti-apoptotic BCL2
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family members, MCL1, Bcl-xL, and BCL2, in the survival of lung ade-
nocarcinoma cells. Although it has been reported that NSCLC cell lines
rarely express BCL2 protein, KRAS-mutant H460 cells are an exception
[24]. H441 and H1975 cells were relatively well-differentiated lung
adenocarcinoma cells expressing TTF-1 (encoded by the NKX2-1 gene),
a representative alveolar epithelial marker, at mRNA and protein levels,
whereas it was hardly detectable in H460 cells (Supplementary Fig.
S4A, B). The lack of TTF-1 expression in H460 cells was consistent with
the phenotype of “large cell carcinoma” [25,26]. We then examined the
expression levels of BCL2, Bcl-xL (encoded by the BCL2L1 gene), and
MCL1 at protein and mRNA levels in these cells. Fig. 3A illustrates that
both H441 and H1975 cells clearly expressed MCL1 and Bcl-xL, but not
BCL2, at protein levels, which was supported by RT-PCR analyses
(Fig. 3B). We then investigated whether dual knockdown of MCL1 and
Bcl-xL through RNAi induced massive apoptosis in H460, H441, and
H1975 cells. Although H460 cells were resistant to the dual knockdown
therapy, H441 and H1975 cells underwent extensive apoptosis, as ex-
pected, so that viability was markedly decreased in the two cell lines
(Fig. 3C–E).
3.4. Verification of MCL1 and Bcl-xL-dependent survival of differentiated
lung adenocarcinoma cells by BH3 mimetics
We next verified these findings using three BH3 mimetics, S63845,
ABT-263, and WEHI-539 (a selective inhibitor of Bcl-xL). BH3 mimetic
monotherapy did not induce apoptosis in the three examined cell lines
(Fig. 4A, B). However, all cell lines clearly underwent apoptosis after
combined therapy by S63845 and ABT-263 (inhibition of MCL1, BCL2,
and Bcl-xL) (Fig. 4A–D). However, combined treatment with S63845
and WEHI-539 (inhibition of MCL1 and Bcl-xL) induced extensive
apoptosis in H441 and H1975 cells, but not H460 cells. This interesting
phenomenon appeared to be caused by the difference in the expression
levels of BCL2 in the three cell lines (Fig. 3A, B). It is likely that H441
and H1975 cells depend critically on MCL1 and Bcl-xL for survival,
whereas H460 cells rely on BCL2 as well as MCL1 and Bcl-xL for sur-
vival. Taken together, these results suggest that the survival of differ-
entiated lung adenocarcinoma cells is highly dependent on MCL1 and
Bcl-xL, and that the dual blockade strategy of the two anti-apoptotic
molecules might be generally efficacious for treatment of differentiated
lung adenocarcinomas irrespective of differences in their driver muta-
tion.
4. Discussion
We have shown that high expression levels of MCL1 mRNA are as-
sociated with unfavorable outcome in lung adenocarcinoma patients,
and that combined therapy by a MEK inhibitor and MCL1 knockdown
(or inhibitor) is an effective treatment for not only KRAS-mutant H441
Fig. 2. Combined therapy by MCL1 knockdown and trametinib prevents H441 cells from growing in vivo. (A) Effects of the combined therapy on xenografts of H441
cells. Mice with NC siRNA-transfected xenografts (n=10) and those with MCL1 siRNA-transfected xenografts (n= 10) were untreated (n=5) or treated (n= 5)
with trametinib (0.6 mg/kg) for 20 days. Drugs were administered once daily by oral gavage. Tumor volumes (means ± SD) were measured after the initiation of
trametinib treatment (day 0). ‘Day 0’ corresponds to day 12 after cell implantation, when AteloGene was also administered. **P < 0.01. (B) Effects of the combined
therapy on xenografts derived from H441 cells. Macroscopic images of tumors resected from mice are shown. The 20 tumor nodules presented were derived from 20
treated mice. (C) Effect of the combined therapy on xenografts of H441 cells. The weight of each tumor, shown in (B), was measured. Columns, mean (n=5);
bars,± SD. **P < 0.01. (D) Pathological examination of xenografts. Representative images (H&E stained) are shown. Scale bars, 50 μm.
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cells, but also EGFR-mutant H1975 cells. For H441 cells, the combined
therapy by trametinib and MCL1 knockdown appeared to be slightly
less efficacious than the combined therapy by trametinib and Bcl-xL
knockdown. However, we believe that MCL1 is still a potential ther-
apeutic target for the treatment of KRAS-mutant lung adenocarcinomas,
because Bcl-xL inhibition by ABT-263 caused thrombocytopenia in a
dose-dependent manner in clinical trials [27,28]. During the prepara-
tion of this article, another study has highlighted the efficacy of com-
bined inhibition of MEK and MCL1 against KRAS-mutant lung adeno-
carcinoma cells [29].
Overexpression of the MCL1 gene has been reported in various he-
matopoietic and solid tumors [30]. Experimental findings in our study
Fig. 3. Dual knockdown of MCL1 and Bcl-xL induces massive apoptosis in H441 and H1975 cells. (A) Western blot analyses of anti-apoptotic BCL2 family proteins in
H460, H441, and H1975 cells. (B) RT-PCR analyses of BCL2, MCL1, and BCL2L1 mRNAs in H460, H441, and H1975 cells. (C) Effects of dual inhibition of MCL1 and
Bcl-xL on H460, H441, and H1975 cells. Cells were transfected with siRNAs as indicated and then cultured for 48 h. Cell viability was then assessed for another 72 h
in triplicate. Results are expressed as means ± SD. **P < 0.01. (D) Crystal violet staining of viable cells. Cells were treated as described in (C). (E) Western blot
analyses of the effects of dual knockdown of MCL1 and Bcl-xL in H460, H441, and H1975 cells. Cells were treated as described in (C).
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suggested that MCL1 plays a certain role in the survival of lung ade-
nocarcinoma cells. Interestingly, H1975 cells were more sensitive to the
combined therapy by MCL1 knockdown and trametinib than H441
cells. It has been reported that MCL1-dependent NSCLC cells generally
express more MCL1 than Bcl-xL at protein levels, and that the ratio of
MCL1 to BCL2L1 mRNA expression in MCL1-dependent cells is two to
10 times higher than that in MCL1-independent cells [31]. This finding
may be applicable to H441 and H1975 cells extensively analyzed in this
study. However, a simpler method would be required to use BH3 mi-
metics such as S63845 in the clinic.
We have also shown that BCL2 is hardly detected in H441 and
H1975 cells, well-differentiated lung adenocarcinoma cell lines, and
that these two cell lines depend critically on MCL1 and Bcl-xL for sur-
vival. It appears that cancer cells are generally dependent on several
anti-apoptotic BCL2 family members, not a single one, for survival [32].
Our findings suggest that dual blockade of MCL1 and Bcl-xL might be
effective for a wide range of cancers except for undifferentiated carci-
nomas, such as H460 lung cancer and PC-3 prostate cancer cells, which
often express BCL2 [24,33]. Such dependency of differentiated carci-
nomas on MCL1 and Bcl-xL for survival is consistent with the findings in
a previous report [34]. However, dual inhibition of MCL1 and Bcl-xL by
BH3 mimetics in vivo might cause severe side effects, and the ther-
apeutic window is yet to be determined [32,35,36]. Much remains to be
studied before concurrent inhibition therapy is available in the clinic.
This study has several limitations. First, although MCL1 mRNA ex-
pression levels were significantly correlated with unfavorable outcomes
of lung adenocarcinoma patients, the correlation between MCL1 pro-
tein expression and OS is yet to be analyzed. Second, trametinib is
available in the clinic, but BH3 mimetics S63845 and ABT-263 used in
the present study are being investigated in clinical trials of hematologic
Fig. 4. Verification of MCL1 and Bcl-xL-dependent survival of differentiated lung adenocarcinoma cells by BH3 mimetics. (A) Effects of the combined therapy by BH3
mimetics on the viability of H460, H441, and H1975 cells. A total of 5× 105 cells were seeded in 6-well plates and then treated with S63845 (0.1 μM) alone, WEHI-
539 (2 μM) alone, ABT-263 (1 μM) alone, the combination of S63845 and WEHI-539 or S63845 and ABT-263, or neither for 72 h. Scale bars, 100 μm. (B) Crystal
violet staining of viable cells. Cells were treated as described in (A). (C) Effects of the combined therapy by S63845 and WEHI-539 or S63845 and ABT-263 on the
viability of H460, H441, and H1975 cells. Cells were treated as described in (A). Cell viability was assessed for 72 h in triplicate. Results are shown as means ± SD.
**P < 0.01. (d) Western blot analyses of the effects of the combined therapies in H460, H441, and H1975 cells. Cells were treated as described in (A).
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tumors and small cell lung cancer (clinicaltrials.gov: NCT02979366 for
S63845; NCT00445198 for ABT-263). It has been indicated that ABT-
263 is not effective as a single agent and causes the side effect of
thrombocytopenia as mentioned above [27,28]. Third, we extensively
analyzed only one KRAS-mutant differentiated lung adenocarcinoma
cell line, H441, in this study, and many more KRAS-mutant cell lines
need to be examined.
In summary, lung adenocarcinomas with high MCL1 mRNA ex-
pression are associated with shorter survival, and combined therapy by
MCL1 knockdown and trametinib substantially suppresses the growth
of KRAS-mutant lung adenocarcinoma H441 cells in vitro and in vivo.
We have also demonstrated that concurrent inhibition of MCL1 and Bcl-
xL induces massive apoptosis in well-differentiated lung adenocarci-
noma H441 and H1975 cells. These findings collectively suggest that
MCL1 plays a certain role in the survival of lung adenocarcinoma cells
and is a potential therapeutic target for the treatment of lung adeno-
carcinomas including the KRAS-mutant subtype.
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